



Press information – for immediate release

December 2, 2004

Coley Pharmaceutical GmbH Receives Award at the Future Congress 2004 „Benchmark NRW“

Dr. Christian Schetter, Vice President European Operations Coley Pharmaceutical Group, USA and Managing Director of Coley Pharmaceutical GmbH, Langenfeld (www.coleypharma.com), accepted this award endowed with a 5.000 Euro distinction in the old House of Parliament in Bonn on November 19th 2004. Coley Pharmaceutical receives this award for the company's innovative product development in the area of their leading discovery research and chemical development and as one of the state-of-the-art pharmacology ventures registered in North Rhine Westfalia, according to the award statement. „We are pleased to receive this award, as it exemplifies that young and innovative companies can also operate successfully in Germany – especially when, as in the case of Coley, they pursue a global approach right from the start“, comments Schetter.

Coley Pharmaceutical Group Inc. was founded 1997 by Prof. Arthur M. Krieg, University of Iowa, USA, Dr. Heather L. Davis, Loeb Institute, Ottawa, Canada and Dr. Joachim Schorr, Qiagen GmbH, Germany. In August of the same year the German GmbH was incorporated; operations with laboratories and offices were started in the „Qiagen Incubator“ in 1998. A first priority was to set up important aspects of the research structure within the company and establish research networks to access the know-how of university groups in Germany and Europe. The corporate strategy was complemented by establishing a group supporting clinical studies in Europe. In January 2001 the GmbH moved to Langenfeld. Today the global structure of Coley Pharmaceutical Group consists of so called „Centres of Excellence“, in which the world class drug discovery and chemical development is located in Germany, while the pharmacology group is located in Canada. The successful product development is coordinated at the headquarters in the US. The Coley Group is

still privately financed. Coley Pharmaceutical is focussed on the development of products in the areas:

- Cancer – Ongoing late Phase II Studies; Results in 2004; Interim results in lung cancer very promising
- Antiviral – New product for the therapy of Hepatitis C Virus in clinical Phase I/II
- Asthma – Significant partnership with Sanofi-Aventis financing product development
- Vaccines - In clinical Phase I with various partners

The „Zukunftskongress“ (Future Congress)

The „Zukunftskongress“ 2004 "Benchmark NRW" is a new forum initiated by the CDU (Christian Democratic Union) in North Rhine Westfalia. Its goal is to build a platform for the dialogue between industry, science and politics to generate impulses for economical growth in North Rhine Westfalia. Associated with the "Zukunftskongress" is an „Innovation Award" as well as two "Promotional Awards" for selected representatives from industry, science, politics and society. This year's main laureate was René Obermann, CEO of T-Mobile International. The second Promotion Award received the company „KTR Kupplungstechnik" registered in Rheine.

Further Information:

Coley Pharmaceutical GmbH
Managing Director
Dr. Christian Schetter
Vice President, European Operations
Coley Pharmaceutical Group, Inc.
Elisabeth-Selbert-Strasse 9
40764 Langenfeld, Germany

Tel.: +49 (0) 2173-3997-2115
Fax: +49 (0) 2173-3997-2399
cschetter@coleypharma.com
www.coleypharma.com

Photo material is available on demand.